202 related articles for article (PubMed ID: 21242980)
1. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.
Yang Y; Tse AK; Li P; Ma Q; Xiang S; Nicosia SV; Seto E; Zhang X; Bai W
Oncogene; 2011 May; 30(19):2207-18. PubMed ID: 21242980
[TBL] [Abstract][Full Text] [Related]
2. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications.
Zhao X; Sternsdorf T; Bolger TA; Evans RM; Yao TP
Mol Cell Biol; 2005 Oct; 25(19):8456-64. PubMed ID: 16166628
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation.
Yang Q; Tang J; Xu C; Zhao H; Zhou Y; Wang Y; Yang M; Chen X; Chen J
J Mol Cell Biol; 2020 Jul; 12(12):933-945. PubMed ID: 32770227
[TBL] [Abstract][Full Text] [Related]
4. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase.
Kirsh O; Seeler JS; Pichler A; Gast A; Müller S; Miska E; Mathieu M; Harel-Bellan A; Kouzarides T; Melchior F; Dejean A
EMBO J; 2002 Jun; 21(11):2682-91. PubMed ID: 12032081
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.
Fu M; Wang C; Wang J; Zhang X; Sakamaki T; Yeung YG; Chang C; Hopp T; Fuqua SA; Jaffray E; Hay RT; Palvimo JJ; Jänne OA; Pestell RG
Mol Cell Biol; 2002 May; 22(10):3373-88. PubMed ID: 11971970
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase.
Jeong BC; Hong CY; Chattopadhyay S; Park JH; Gong EY; Kim HJ; Chun SY; Lee K
Mol Endocrinol; 2004 Jan; 18(1):13-25. PubMed ID: 14576337
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
8. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
9. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.
Gaughan L; Logan IR; Cook S; Neal DE; Robson CN
J Biol Chem; 2002 Jul; 277(29):25904-13. PubMed ID: 11994312
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion.
Karvonen U; Jänne OA; Palvimo JJ
Exp Cell Res; 2006 Oct; 312(16):3165-83. PubMed ID: 16860317
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
Welsbie DS; Xu J; Chen Y; Borsu L; Scher HI; Rosen N; Sawyers CL
Cancer Res; 2009 Feb; 69(3):958-66. PubMed ID: 19176386
[TBL] [Abstract][Full Text] [Related]
12. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
Zheng Z; Cai C; Omwancha J; Chen SY; Baslan T; Shemshedini L
J Biol Chem; 2006 Feb; 281(7):4002-12. PubMed ID: 16361251
[TBL] [Abstract][Full Text] [Related]
13. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation.
Wu R; Cui Y; Yuan X; Yuan H; Wang Y; He J; Zhao J; Peng S
Toxicol Lett; 2014 Sep; 229(2):405-13. PubMed ID: 25014244
[TBL] [Abstract][Full Text] [Related]
14. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
15. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
16. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.
Rytinki M; Kaikkonen S; Sutinen P; Paakinaho V; Rahkama V; Palvimo JJ
Mol Cell Biol; 2012 Oct; 32(20):4195-205. PubMed ID: 22890844
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor signaling: mechanism of interleukin-6 inhibition.
Jia L; Choong CS; Ricciardelli C; Kim J; Tilley WD; Coetzee GA
Cancer Res; 2004 Apr; 64(7):2619-26. PubMed ID: 15059919
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract][Full Text] [Related]
19. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism.
Blakeslee WW; Wysoczynski CL; Fritz KS; Nyborg JK; Churchill ME; McKinsey TA
Cell Signal; 2014 Dec; 26(12):2912-20. PubMed ID: 25220405
[TBL] [Abstract][Full Text] [Related]
20. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription.
Nishida T; Yasuda H
J Biol Chem; 2002 Nov; 277(44):41311-7. PubMed ID: 12177000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
